Loading stock data…
WST
$334.66+14.91 (+4.66%)
After Hours$334.41-0.25 (-0.07%)· Last close Jun 9
West Pharmaceutical Services, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
West Pharmaceutical Services, Inc. in the Healthcare sector is trading at $334.66 with a market capitalization of $22.8B. Wall Street consensus targets $352.36 (14 analysts), implying a +5.3% move over the next 12 months. The stock is currently near its 52-week high of $336.82, remaining 24.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$334.66
Potential Upside
5.5%
Whystock Fair Value$353.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$352.36+5.3%
Range$310.00 – $400.00
Fundamentals
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Pro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
43.13
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.26%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.15%
Volume
Today's trading volume
753,767
Recent News
Stocks Climb on an AI-Led Rebound
The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More
Pre-Market Stock Futures: Futures are trading higher after the bulls tried to rally stocks on Monday, after the drubbing they took on Friday, and it looks the same way today. While it was a partial victory on Monday, by the close, the huge gains from the morning were cut in half, and the Dow Jones ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More
Wolfe Research Says West Pharmaceutical Services (WST) is Positioned to Benefit from Injectable Drug Growth
With a net profit margin of 16.85%, West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. Wolfe Research analyst Mike Polark upgraded West Pharmaceutical Services, Inc. (NYSE:WST) to Outperform from Peer Perform on June 2. He also assigned a $375 price target to the stock. The analyst […]
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
MMSI leans on therapeutic strength, an oncology acquisition and a new stent launch, but tariffs, OEM weakness and China pressure shadow 2026.